WavoDyne Therapeutics is developing a novel group of therapeutics to treat cognitive disorders associated with neurodegenerative disease. Our lead product, URMC-099, will enter clinical dev. in 1Q2017, and will be submitted for FDA approval in 2021. We project this product will generate $1 bn annual revenues in year 5 of its commercialization. URMC-099, is a potent inhibitor of a group of MAP Kinases known as Mixed Lineage Kinase inhibitors.